AUTHOR=Li Xiaodan , Zhang Shengzhao , Zhou Yiling , Liu Ying , Zhou Youlian , Li Sheyu , Su Na 

TITLE=Deficiencies in Planning Interventional Trial Registration of COVID-19 in China

JOURNAL=Frontiers in Medicine

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.618185

DOI=10.3389/fmed.2021.618185

ISSN=2296-858X

ABSTRACT=<p><bold>Background:</bold> The coronavirus disease 2019 (COVID-19) pandemic has affected the world since late 2019. The efforts to control the spread of the virus need to be supported by credible evidence. Therefore, we analyzed the rationality of the timeline and geographic distribution of COVID-19 trial registration in mainland China.</p><p><bold>Methods:</bold> We searched the Chinese Clinical Trial Registry (ChiCTR, <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.chictr.org.cn/</ext-link>) and International Clinical Trials Registry Platform (ICTRP, <ext-link ext-link-type="uri" xlink:href="https://www.who.int/ictrp/en/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.who.int/ictrp/en/</ext-link>) using keywords including novel coronavirus, coronavirus pneumonia, 2019-nCoV, COVID-19, and SARS-COV-2 from 1 December 2019 to 27 April 2020 and included interventional randomized and non-randomized trials including patients with confirmed cases of COVID-19 in mainland China. The registered trials were reviewed, and data were independently extracted by two reviewers based on the inclusion criteria.</p><p><bold>Results:</bold> A total of 263 registered interventional trials were included in the study. We defined the sample size index (SI) as the total number of patients needed by the trials divided by the total number of patients diagnosed with COVID-19. A total of 84,341 patients had been diagnosed with COVID-19 in China as of 26 April 2020, and the included trials had a combined sample size of 31,156 patients (SI: 0.37). After control of the COVID-19 epidemic was achieved in China (February 18, 2020), the SI was 1.54, suggesting that the number of patients needed by the trials was greater than the number of newly diagnosed patients. The SIs in 8 out of 26 provinces in mainland China were &gt;1.</p><p><bold>Conclusions:</bold> Our results suggested a clear over registration of COVID-19 trials in China, especially after control of the pandemic was achieved, preventing the generation of high-quality evidence.</p>